Viyash Scientific Limited
All news and filings related to Viyash Scientific Limited.
View all news & filings- Medium impact
Viyash Scientific subsidiary gets Italian approval for BioForLife acquisition; completion revised
Viyash Scientific subsidiary, Alivira Animal Health, received Italian FDI approval for its acquisition of BioForLife Italia S.r.l. The transaction completion timeline has been revised and is now expected within two months from September 08, 2026.
Read the summary - Low impact
Viyash Scientific Allots 6.12 Lakh Equity Shares Under ESOP Plans
Viyash Scientific allotted 6,12,773 equity shares under ESOP 2020 and ESOP 2026. 2,30,001 shares were issued at ₹86 and 3,82,772 shares at ₹101. This increases the company's issued and paid-up capital to ₹88,10,40,722.
Read the summary - High impact
Viyash Scientific Q1 FY27 Earnings Call Transcript Released
Viyash Scientific reported strong Q1 FY27 results with revenue at ₹946 crore (up 20% YoY) and PAT at ₹79 crore (more than doubled YoY). EBITDA rose 59% to ₹205 crore, with margins at 21.6%. Net debt reduced to ₹86 crore. The company is set to acquire Bio For Life in Italy, strengthening its companion animal health segment.
Read the summary - Low impact
Viyash Scientific releases audio recording of earnings call for Q1 FY27 results
Viyash Scientific Limited has released the audio recording of its earnings call held on August 12, 2026. The call discussed the unaudited financial results for the quarter ended June 30, 2026. The recording is available on the company's website.
Read the summary - Low impact
Viyash Scientific Publishes Unaudited Financial Results for Q1 FY27
Viyash Scientific Limited announced its unaudited financial results for the quarter ended June 30, 2026. These results were published on August 12, 2026, in The Financial Express and Nava Telangana newspapers.
Read the summary - High impact
Viyash Scientific Q1 FY27 Results: Revenue ₹9,464 Crore, EBITDA ₹2,047 Crore
Viyash Scientific reported Q1 FY27 revenue of ₹9,464 crore and EBITDA of ₹2,047 crore, up 19.5% and 59.2% YoY, respectively. EBITDA margin improved to 21.6%. The company is acquiring Bio For Life in Italy, with closing expected in September 2026, to expand its companion animal segment.
Read the summary - Medium impact
Viyash Scientific AGM: All resolutions passed, including director re-appointments and AoA adoption.
Viyash Scientific Limited's AGM on August 11, 2026, saw all resolutions pass. Key approvals include audited financial statements for FY26, re-appointments of directors Dr. Haribabu Bodepudi and Mr. Rajaram Narayanan, and adoption of a new Articles of Association. Cost Auditor remuneration was also ratified for FY26 and FY27.
Read the summary - Low impact
Viyash Scientific Limited Holds 41st AGM on August 11, 2026
Viyash Scientific Limited held its 41st AGM on August 11, 2026, via VC/OAVM. Key resolutions included adopting FY26 financial statements, re-appointing directors, and ratifying cost auditor remuneration. E-voting results will be announced later.
Read the summary - High impact
Viyash Scientific Q1 FY27 Revenues Up 19.5% to ₹946.4 Crore, PAT Soars 114.9%
Viyash Scientific reported Q1 FY27 results with revenues at ₹946.4 crore (up 19.5%) and PAT at ₹79.3 crore (up 114.9%). EBITDA grew 59.2% to ₹204.7 crore. The company highlighted the acquisition of Bio For Life in Italy as a strategic step. An earnings call is scheduled for August 12, 2026.
Read the summary - Medium impact
Viyash Scientific Board Approves Q1 FY27 Results, ESOP Allotment & Vietnam Subsidiary
Viyash Scientific approved Q1 FY27 results, including standalone and consolidated financials. The company approved the allotment of 10,30,775 equity shares under its ESOP Scheme 2026. It will also incorporate a subsidiary in Vietnam and invest up to ₹400.02 crore in its subsidiary Alivira Animal Health Limited through a rights issue.
Read the summary - Medium impact
Viyash Scientific Approves Q1 FY27 Results, ESOP Allotment & Vietnam Subsidiary
Viyash Scientific approved Q1 FY27 results. The company approved allotment of 10,30,775 equity shares under ESOP Scheme 2026. It will also incorporate a subsidiary in Vietnam and invest up to ₹400.02 crore in Alivira Animal Health Limited via rights issue.
Read the summary - Low impact
Viyash Scientific schedules Q1 FY27 earnings conference call for August 12, 2026
Viyash Scientific Limited will hold its Q1 FY27 earnings conference call on August 12, 2026, at 3:30 PM IST. Management will discuss financial results for the quarter ended June 30, 2026. Dial-in details are available on the company's website.
Read the summary - Low impact
Viyash Scientific Allots 20.01 Lakh Equity Shares Under ESOP 2020
Viyash Scientific Limited allotted 20,01,336 equity shares of ₹2 each at an exercise price of ₹86 per share under its ESOP 2020. The company's issued and paid-up share capital increased to ₹87.78 crore.
Read the summary - Medium impact
Viyash Scientific Subsidiary Executes SPA to Acquire BioForLife Italia for EUR 16.976 Million
Viyash Scientific Limited's subsidiary, Alivira Animal Health, executed an SPA to acquire 100% of BioForLife Italia S.r.l. The acquisition consideration is approximately EUR 16.976 million, with EUR 15.0 million due at closing and the remainder as deferred consideration. Transaction completion is subject to Italian FDI clearance.
Read the summary - Low impact
Viyash Scientific Ltd. Announces 41st AGM on August 11, 2026
Viyash Scientific Limited will hold its 41st Annual General Meeting on August 11, 2026. Shareholders will be informed about e-voting procedures. Advertisements were published on July 18, 2026.
Read the summary - Low impact
Viyash Scientific Announces 41st AGM on August 11, 2026, Shares Annual Report
Viyash Scientific Limited will hold its 41st AGM on August 11, 2026, at 4:00 PM IST via Video Conference. The company has released its Annual Report for FY 2025-26, accessible online. Shareholders are urged to register email IDs for electronic communication and update KYC details.
Read the summary - Low impact
Viyash Scientific Files Business Responsibility and Sustainability Report for FY26
Viyash Scientific Limited has released its Business Responsibility and Sustainability Report for FY 2025-26. The report is an integral part of the Annual Report and is filed as per SEBI regulations. It is available on the company's website.
Read the summary - Low impact
Viyash Scientific Ltd. Announces 41st AGM on August 11, 2026; E-voting from August 7-10
Viyash Scientific Limited will hold its 41st AGM on August 11, 2026, via VC/OAVM. Shareholders can e-vote from August 7-10, 2026. The AGM will consider FY26 financial statements, re-appointments of key directors, and ratification of cost auditor remuneration. A new set of Articles of Association will also be proposed.
Read the summary - Low impact
Viyash Scientific Announces 41st AGM on Aug 11, 2026, with E-voting Facility
Viyash Scientific Limited will hold its 41st Annual General Meeting on August 11, 2026, at 4:00 PM IST. Shareholders can participate via e-voting. Details on email registration are also provided.
Read the summary - Low impact
Viyash Scientific receives SEBI administrative warning for SDD maintenance.
Viyash Scientific Limited received an administrative warning letter from SEBI regarding the maintenance of its Structured Digital Database (SDD) for the period June 26, 2024, to October 18, 2024. The company stated that this has no impact on its financials or operations.
Read the summary - Low impact
Viyash Scientific Ltd: Certificate under SEBI (Depositories and Participants) Regulations, 2018
Viyash Scientific Limited received a certificate from its Registrar and Share Transfer Agent, KFin Technologies Limited, for the quarter ended June 30, 2026. This confirms compliance with SEBI (Depositories and Participants) Regulations, 2018, regarding dematerialization/rematerialization of securities.
Read the summary - Medium impact
Viyash Scientific Limited Shareholders Approve Director Appointments and CEO Incentive
Viyash Scientific Limited shareholders approved the appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as directors. A one-time performance incentive for Mr. Rajaram Narayanan, Whole-time Director & CEO - Animal Health, was also approved. The resolutions passed with a requisite majority.
Read the summary - Low impact
Viyash Scientific to Host 'Viyash Investor Day - 2026' on June 25
Viyash Scientific Limited will host 'Viyash Investor Day - 2026' on June 25, 2026, in Mumbai. The event will be held physically with investors and analysts. Publicly available information will be discussed, and presentations will be shared beforehand on stock exchanges and the company website.
Read the summary - Low impact
Viyash Scientific Dispatches Notice of Postal Ballot, Newspaper Ads Published
Viyash Scientific Limited has completed the dispatch of its Notice of Postal Ballot. Newspaper advertisements confirming this were published on May 30, 2026, in Financial Express and Nava Telangana. The notice will also be hosted on the company's website.
Read the summary - Medium impact
Viyash Scientific Announces Postal Ballot for Director Appointments & Performance Incentive
Viyash Scientific is seeking shareholder approval via postal ballot for appointing Mr. Amit Jain and Mr. Abhiroop Jayanthi as directors. Shareholders will also vote on a ₹4 crore performance incentive for Whole-time Director & CEO - Animal Health, Mr. Rajaram Narayanan. Remote e-voting is open from May 30 to June 28, 2026.
Read the summary - Low impact
Viyash Scientific Limited Publishes Newspaper Advertisement for IEPF Share Transfer
Viyash Scientific Limited published a notice regarding the transfer of shares to the IEPF. This action follows SEBI regulations and the Companies Act. Individual notices have been sent to eligible shareholders.
Read the summary - Low impact
Viyash Scientific Withdraws India Ratings, Continues With ICRA Ratings
Viyash Scientific Limited has withdrawn its bank loan facility ratings from India Ratings and Research. The company's bank loan facilities, amounting to ₹350 million (35 crore), have been withdrawn. Viyash Scientific continues to maintain its ratings with ICRA Ratings.
Read the summary - High impact
Viyash Scientific Q4 FY26 Earnings Transcript Released; Strong Growth Reported
Viyash Scientific released its Q4 FY26 earnings transcript, reporting its strongest quarter with EBITDA over ₹200 crore. FY26 EBITDA grew 59.6% and PAT by 1,324%. Total revenue for FY26 reached ₹3,420 crore. The company is focusing on growth in animal and human health formulations, API, and CDMO businesses. Key priorities for FY27 include merger synergies and operational improvements.
Read the summary - Low impact
Viyash Scientific Announces Audio Recording of Earnings Call for Quarter and Year Ended March 31, 2026
Viyash Scientific has released the audio recording of its earnings call held on May 20, 2026, for the audited financial results (consolidated and standalone) for the quarter and year ended March 31, 2026. The recording is available on the company's website.
Read the summary - Low impact
Viyash Scientific Publishes Audited Financial Results Extract in Newspapers
Viyash Scientific Limited published audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The publication occurred on May 20, 2026, in The Financial Express and Nava Telangana newspapers as per SEBI regulations.
Read the summary - High impact
Viyash Scientific FY26 Revenue ₹34,203 Million, Up 13.8% YoY; EBITDA at ₹7,025 Million, Up 59.6%
Viyash Scientific reported FY26 revenue of ₹34,203 million, a 13.8% YoY increase, and EBITDA of ₹7,025 million, up 59.6% YoY. Q4 revenue was ₹9,200 million, up 19.1% YoY, with EBITDA at ₹2,001 million. Net debt to LTM EBITDA improved to 0.2x from 1.0x in FY25. The company's merger is approved, focusing on synergy realization, and evaluating inorganic growth opportunities.
Read the summary - High impact
Viyash Scientific Q4 FY26 Revenue Up 19.1% to ₹9,200 Million, EBITDA Up 63.8%
Viyash Scientific reported Q4 FY26 revenue of ₹9,200 million, a 19.1% increase, and EBITDA of ₹2,001 million, up 63.8%. PAT for Q4 FY26 was ₹664 million, up 306%. FY26 revenue reached ₹34,203 million, up 13.8%, with EBITDA at ₹7,025 million, up 59.6%. Dr. Hari Babu Bodepudi noted the successful integration of operations. An earnings call is scheduled for May 20, 2026, at 16:00 IST.
Read the summary - Medium impact
VIYASH: Audited FY26 Results Approved, ESOP 2026 Granted, AOA Adopted
Viyash Scientific Limited's Board approved audited standalone and consolidated financial results for the year ended March 31, 2026. They adopted a new AOA, pending shareholder approval, and granted 1,30,98,000 stock options under the 'Viyash Scientific Limited Employee Stock Option Scheme 2026'. No dividend was recommended for FY 2025-26.
Read the summary - Medium impact
Viyash Scientific FY26: Revenue ₹13,820.6 Crore, Net Profit ₹758.7 Crore; ESOP 1.3 Crore Shares Granted
Viyash Scientific Limited's board approved audited financial results for the year ended March 31, 2026, with revenue from operations at ₹13,820.6 crore (₹138,206 million) and a profit after tax of ₹758.7 crore (₹7,587 million). The board also approved granting 1.3 Crore (13,098,000) stock options to eligible employees under the 'Viyash Scientific Limited Employee Stock Option Scheme 2026'. No dividend was recommended for FY 2025-26.
Read the summary - Medium impact
Viyash Scientific Limited Announces Demise of AVP – Legal and Compliance, Mr. Phillip Trott
Viyash Scientific Limited announced the demise of Mr. Phillip Trott, AVP – Legal and Compliance, a senior management member. His cessation from the company was effective May 15, 2026, due to his passing.
Read the summary - Low impact
Viyash Scientific Schedules Q4 FY26 Earnings Conference Call for May 20, 2026
Viyash Scientific Limited has scheduled a conference call for May 20, 2026, at 4:00 PM IST to discuss its Q4 FY26 financial results. Key management, including the MD & Group CEO and CFO, will participate.
Read the summary - Medium impact
Viyash Scientific's Bank Facility Ratings Upgraded to IND AA- by India Ratings
India Ratings and Research has upgraded Viyash Scientific Limited's bank facilities rating. Long-term rating is now 'IND AA-' with a Stable Outlook, and short-term rating is 'IND A1+'. The rated bank loan facilities amount to INR 350 million.
Read the summary - Low impact
Viyash Scientific Allots 8,000 Equity Shares Under ESOP 2020
Viyash Scientific Limited has allotted 8,000 equity shares under its ESOP 2020 at an exercise price of Rs. 86 per share. This allotment increases the company's paid-up equity share capital to Rs. 87,37,50,954.
Read the summary - Medium impact
Viyash Scientific gets [ICRA]AA-(Stable) rating for Rs 185 Cr working capital facilities
Viyash Scientific Limited has received an upgraded credit rating of [ICRA]AA-(Stable) for its Long-term Fund Based Working Capital Facilities totaling ₹185.00 crores. This rating, communicated on April 22, 2026, is an improvement from its previous rating.
Read the summary - Medium impact
Viyash Scientific Appoints Amit Jain & Abhiroop Jayanthi as Additional Directors
Viyash Scientific Limited appointed Amit Jain and Abhiroop Jayanthi as Additional Directors, effective April 22, 2026. Both represent Carlyle group. The company also revised its ESOP 2026 pool to 1,30,98,000 stock options.
Read the summary - Medium impact
Viyash Scientific Appoints Amit Jain & Abhiroop Jayanthi as Directors, Revises ESOP Pool
Viyash Scientific appointed Amit Jain and Abhiroop Jayanthi as Additional Directors. The company also revised its ESOP 2026 pool from 1,34,75,000 to 1,30,98,000 stock options. Both appointments are effective April 22, 2026, subject to shareholder approval.
Read the summary - Low impact
Viyash Scientific Changes Website Domain and Email IDs
Viyash Scientific Limited has updated its website domain to www.viyash.com from www.sequent.in. Consequently, authorized personnel's email IDs have also been changed, with the new investor relations email being investorrelations@viyash.com.
Read the summary - Low impact
Viyash Scientific Files SEBI Compliance Certificate for Q4 FY26
Viyash Scientific Limited has submitted a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The certificate confirms the furnishing of dematerialization/rematerialization details to stock exchanges.
Read the summary - Low impact
Viyash Scientific Allots 16,667 Equity Shares Under ESOP 2020
Viyash Scientific Limited allotted 16,667 equity shares under its ESOP 2020 plan at an exercise price of ₹86 per share. This increases the company's paid-up equity share capital to ₹87,37,34,954.
Read the summary - Low impact
Viyash Scientific Clarifies Director Resignation Date Error
Viyash Scientific Limited clarified a date error in a previous filing. The resignation of Non-Executive Directors Dr. Fabian Kausche and Mr. Gregory Andrews, effective March 30, 2026, was incorrectly dated March 30, 2025, on the covering letter. The company has corrected this oversight.
Read the summary - Low impact
Viyash Scientific Limited: Two Non-Executive Directors Resign
Dr. Fabian Kausche and Mr. Gregory Andrews are resigning as Non-Executive Directors from Viyash Scientific Limited. Their resignations are effective from March 30, 2026, citing personal reasons and other commitments.
Read the summary - Low impact
Viyash Scientific Limited Closes Trading Window from April 1, 2026, for Financial Results
Viyash Scientific Limited will close its trading window from April 1, 2026. The closure is in effect until 48 hours after the declaration of audited financial results for the quarter and year ending March 31, 2026. The board meeting date for approving these results will be intimated later.
Read the summary - Medium impact
Viyash Scientific Limited Shareholders Approve Key Appointments and ESOPs
Viyash Scientific Limited shareholders approved four special resolutions via postal ballot. Key approvals include the appointment of Dr. Haribabu Bodepudi as MD & Group CEO, Mr. Rajaram Narayanan as Whole-time Director, and Mr. Srinivas Vasireddy as Whole-time Director (Executive). Options for over 1% of issued capital were also granted.
Read the summary - Low impact
Viyash Scientific Limited Completes Distribution of Fractional Share Proceeds
Viyash Scientific Limited has completed the distribution of sale proceeds from fractional shares to eligible shareholders. The fractional shares were sold on February 27, 2026, and proceeds were distributed on March 6 and March 9, 2026, as per the composite scheme of amalgamation.
Read the summary - Low impact
Viyash Scientific Allots 1.2 Lakh Equity Shares Under ESOP Plan
Viyash Scientific allotted 1,20,000 equity shares under its ESOP 2020 plan at an exercise price of ₹86 per share. This increases the company's paid-up capital to ₹87,37,01,620, comprising 43,68,50,810 equity shares.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio